Andere talen Rani Therapeutics Holdings, Inc.

Aandelen

RANI

US7530181004

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,38 ^USD	-4,78%		-4,63%	+92,17%

27/03	RANI THERAPEUTICS HOLDINGS, INC. : Canaccord Genuity herhaalt koopadvies voor het aandeel	ZM
25/03	RANI THERAPEUTICS HOLDINGS, INC. : HC Wainwright handhaaft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update	20/03
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	18/03
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	15/03
Rani Therapeutics : RT-111 Phase 1 Data Presentation	12/03
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)	05/02
Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111)	05/02
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)	09/01
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope	14/12
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist	14/12
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	01/12
Sector Update: Health Care	01/12
Rani Therapeutics Stock Climbs After Share Purchase by CEO	01/12
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update	08/11
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results	01/11
Rani Therapeutics Holdings, Inc. Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform	01/11
The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study	25-10-23
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Supporting the Safety and Tolerability of the RaniPill® Drug Delivery Platform Following 60-Day Repeat Administration	25-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Rani Therapeutics Holdings, Inc.

Aandelen

RANI

US7530181004

Andere talen

Filters